logo
Idaho doctor, patients sue over new law halting public benefits to immigrants in US unlawfully

Idaho doctor, patients sue over new law halting public benefits to immigrants in US unlawfully

BOISE, Idaho (AP) — An Idaho doctor and four residents are challenging a new state law that halts some of the few public benefits available to people living in the U.S. unlawfully, including a program that provides access to life-saving HIV and AIDS medication for low income patients.
The ACLU of Idaho filed the federal lawsuit Thursday night on behalf of Dr. Abby Davids and four people with HIV who are not named because they are immigrants without lawful permanent residency.
The complaint says the new law is vague, contradicts federal law and makes it impossible for health care providers to determine exactly what kind of
immigration
status is excluded and how to verify that status for patients. They want a judge to grant them class-action status, expanding any ruling to other impacted people.
Dozens of patients treated by one Boise-area clinic stand to lose access to HIV and AIDS medication under the law, according to the complaint, including several cared for by Davids.
'Withdrawing HIV treatment from her patients will not only have
devastating consequences
on their health, it raises the public health risk of increased HIV transmission,' the ACLU wrote in the lawsuit. 'When her patients are undetectable, they cannot transmit the virus. Without HIV treatment, however, they cannot maintain an undetectable viral level and therefore are able to transmit the virus to others.'
The new Idaho law takes effect July 1, and appears to be the first limiting public health benefits since President Donald Trump
ordered federal agencies
to enhance eligibility verification and ensure that public benefits aren't going to ineligible immigrants.
The law requires people to verify that they are legal U.S. residents to receive public benefits like communicable disease testing, vaccinations, prenatal and postnatal care for women, crisis counseling, some food assistance for children and even access to food banks or soup kitchens that rely on public funding.
Federal law generally prohibits immigrants in the U.S. illegally from receiving taxpayer-funded benefits like Medicare, Medicaid, Temporary Assistance for Needy Families and Social Security. But there are some exceptions for things like emergency medical care and other emergency or public health services.
Idaho's law still allows for emergency medical services. But in a June 18 letter to health care providers, Idaho Division of Public Health administrator Elke Shaw-Tulloch said HIV is a long-term condition and not an emergency — so people must verify their lawful presence in order to get benefits through the federal
Ryan White HIV/AIDS Program
.
The HIV patients challenging the new law include a married couple from Columbia with pending asylum applications, a man who was brought to the U.S. when he was just 4 years old and has Deferred Action for Childhood Arrivals status until next year, and a man from Mexico who has been living and working in Idaho since 2020.
One of the patients said she and her husband were diagnosed with HIV in 2019 and immediately started antiretroviral therapy, receiving the medications at no cost through the Ryan White HIV/AIDS Program. The medication has lowered the viral load in her body enough that it is now undetectable, she wrote in a court filing, ensuring that she won't transmit the virus to others.
'My medication protected my daughter while I was pregnant because it prevented me from transmitting HIV to her during pregnancy,' she wrote.
The treatment allows her to be with her child, watching her grow, she said.
Davids has been trying for weeks to get clarity from the Idaho Department of Health and Welfare about exactly what kind of verification her patients will have to show, and exactly which kinds of immigration status are considered 'lawful.' But the state has yet to provide clear direction, according to the complaint.
'I am really scared about what this means for many of our patients. Their lives will now be in jeopardy,' Davids wrote in a May 30 email to the Department of Health and Welfare.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Yahoo

time40 minutes ago

  • Yahoo

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Yahoo

timean hour ago

  • Yahoo

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Planned Parenthood isn't the only loser in Supreme Court case. Women lose, too.
Planned Parenthood isn't the only loser in Supreme Court case. Women lose, too.

USA Today

timean hour ago

  • USA Today

Planned Parenthood isn't the only loser in Supreme Court case. Women lose, too.

While Democrats have shied away from talking about abortion since the 2024 presidential election, it is still an issue Republicans are rallying around. Almost three years to the day since the U.S. Supreme Court overturned Roe v. Wade, the justices have once again made a decision that will limit access to reproductive care. This time, they're explicitly coming after Planned Parenthood. On Thursday, June 26, the Supreme Court ruled in a decision that could allow states to keep Medicaid dollars from the organization. In the 6-3 ruling, the justices determined that individuals could not sue to choose their health care provider after a patient sued South Carolina to receive reproductive care from Planned Parenthood. By making this decision, the courts are potentially shutting Planned Parenthood out of millions of dollars that would go to necessary health care options like birth control, cancer screenings and testing for sexually transmitted infections. It's a ruling that, like Justice Ketanji Brown Jackson pointed out in her dissent, is going to harm people who rely on Planned Parenthood for their care. The plan was always to end abortion in every state It's just another instance of conservatives ignoring the realities of women's health care in favor of their beliefs, and a reminder that abortion continues to be a Republican target. It's also a reminder that we'll be living in this dystopian health care nightmare for a very, very long time. While Democrats have shied away from talking about abortion since the 2024 presidential election, it is still an issue Republicans are rallying around. They were never going to be satisfied with simply returning abortion rights back to the states, the plan was always to eradicate the health care procedure nationwide. Opinion: Who would want to have babies under a Trump administration? Not me. In May, Health and Human Services Secretary Robert F. Kennedy Jr. ordered the Food and Drug Administration to review mifepristone, an abortion medication, because of a study from a conservative think tank that relies on flawed data. The majority of abortions in 2023 were medication abortions. If mifepristone were suddenly taken off the market, it would have huge ramifications for patients across the country. Planned Parenthood was also already struggling after President Donald Trump froze federal funding to more than 100 clinics earlier this year. It has led clinics across the country to shut down. His One Big Beautiful Bill Act also would block Medicaid patients from seeking care at Planned Parenthood, which could lead to more closures. None of this is happening in a vacuum. All of these Republican attacks amount to a nationwide assault on abortion rights, no matter where one is located in the country. Millions of people could soon lose access to the care they need because of the Republican agenda. Abortion bans aren't working. Defunding Planned Parenthood won't change that. Despite these targeted attacks on abortion, the procedure hasn't become less popular in the years following the Dobbs v. Jackson Women's Health Organization decision. In 2024, there was actually an increase in abortions, with a quarter of those procedures occurring via telehealth for medication. Public opinion on abortion has remained steady, with Pew Research Center reporting that 63% of Americans supported abortion in all or most cases in 2024. Opinion: Democrats don't need to move to the center. Mamdani proves progressives can win. Clearly, Republican leaders are only listening to a small subset of their constituency when they decide to go after Planned Parenthood. They do not listen to the millions of people who have benefited from the wide range of services that the organization provides. Instead, they would rather spread falsehoods about abortion and how it is funded. They will not be happy until abortions are nearly impossible to obtain, even when someone's life is at risk. The Supreme Court's latest cruel decision shows that we are still living with the long-term repercussions of having Trump nominate three justices to the bench. And this is just the beginning. It's clear nothing is going to stop Republicans from attacking Planned Parenthood until it's unable to function because of a lack of government funding. It's shameful that they continue to put a political agenda ahead of the health care needs of women. It's also not changing anytime soon. Follow USA TODAY columnist Sara Pequeño on X, formerly Twitter: @sara__pequeno

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store